pancreatic ductal adenocarcinoma

[Oncogene] Researchers identified a key regulator of macropinocytosis for the survival of tumor cells in a low amino acid environment in pancreatic ductal adenocarcinoma.

[Oncogene] Scientists performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC, where they noted marked upregulation of gastrokine proteins.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated that the multispecificity BET/EP300 inhibitor XP-524 has pronounced single-agent efficacy in vitro, in vivo, and ex vivo human PDAC slice cultures, functioning in part by attenuating oncogenic KRAS signaling.

[Journal of Pathology Clinical Research] The authors investigated the expression of two PD-1 ligands, PD-L1 and PD-L2, in pancreatic ductal adenocarcinoma, analysed their role in survival, and explored their correlation with clinicopathological features, immune infiltration, and DNA damage response molecules.

[Pathology International] Analysis of MXRA8 expression in human pancreatic ductal adenocarcinoma samples showed that MXRA8 was differentially co-expressed with other cancer-associated fibroblasts markers.

[Communications Biology] By analysing publicly available transcriptomic data of patient samples and cell lines, researchers identified here two specific glycan profiles in pancreatic ductal adenocarcinoma that correlated with progression, clinical outcome and epithelial to mesenchymal transition status.